DD220026A5 - Verfahren zur herstellung von in 3-stellung amino-substituierten pyridazin-derivaten - Google Patents

Verfahren zur herstellung von in 3-stellung amino-substituierten pyridazin-derivaten Download PDF

Info

Publication number
DD220026A5
DD220026A5 DD84259650A DD25965084A DD220026A5 DD 220026 A5 DD220026 A5 DD 220026A5 DD 84259650 A DD84259650 A DD 84259650A DD 25965084 A DD25965084 A DD 25965084A DD 220026 A5 DD220026 A5 DD 220026A5
Authority
DD
German Democratic Republic
Prior art keywords
group
alk
formula
hydrobromide
pyridazine
Prior art date
Application number
DD84259650A
Other languages
German (de)
English (en)
Inventor
Jean-Pierre Chambon
Kathleen Biziere
Camille-Georges Wermuth
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of DD220026A5 publication Critical patent/DD220026A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
DD84259650A 1983-01-27 1984-01-26 Verfahren zur herstellung von in 3-stellung amino-substituierten pyridazin-derivaten DD220026A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8301234A FR2540113A1 (fr) 1983-01-27 1983-01-27 Acides derives de la pyridazine actifs sur le systeme nerveux central

Publications (1)

Publication Number Publication Date
DD220026A5 true DD220026A5 (de) 1985-03-20

Family

ID=9285330

Family Applications (1)

Application Number Title Priority Date Filing Date
DD84259650A DD220026A5 (de) 1983-01-27 1984-01-26 Verfahren zur herstellung von in 3-stellung amino-substituierten pyridazin-derivaten

Country Status (27)

Country Link
US (1) US4721711A (fi)
EP (1) EP0117779B1 (fi)
JP (1) JPS59141564A (fi)
KR (1) KR910000638B1 (fi)
AR (1) AR240045A1 (fi)
AT (1) ATE48417T1 (fi)
AU (2) AU2372984A (fi)
CA (1) CA1238637A (fi)
DD (1) DD220026A5 (fi)
DE (1) DE3480653D1 (fi)
DK (1) DK162985C (fi)
ES (1) ES529081A0 (fi)
FI (1) FI78691C (fi)
FR (1) FR2540113A1 (fi)
HU (1) HU193890B (fi)
IE (1) IE57054B1 (fi)
IL (1) IL70756A (fi)
MA (1) MA20018A1 (fi)
NO (1) NO840313L (fi)
NZ (1) NZ206945A (fi)
OA (1) OA07644A (fi)
PH (1) PH21162A (fi)
PL (1) PL142340B1 (fi)
PT (1) PT77993B (fi)
SG (1) SG93690G (fi)
YU (1) YU14284A (fi)
ZA (1) ZA84502B (fi)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2540113A1 (fr) * 1983-01-27 1984-08-03 Sanofi Sa Acides derives de la pyridazine actifs sur le systeme nerveux central
EP0190563B1 (de) * 1985-01-14 1989-08-02 Boehringer Ingelheim Kg Neue 12-Amino-pyridazino[4',5':3,4]pyrrolo-[2,1-a]isochinoline, Verfahren zu ihrer Herstellung und ihre Verwendung
US5082939A (en) * 1987-01-08 1992-01-21 I.S.F. Societa Per Azioni Pyridazine derivatives
US5106973A (en) * 1987-11-23 1992-04-21 Janssen Pharmaceutica N.V. Pyridzainamine derivatives
FR2663326B2 (fr) * 1989-11-17 1992-10-16 Sanofi Sa Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant.
US5631255A (en) * 1989-02-07 1997-05-20 Sanofi Pyridazine derivatives
FR2668151A1 (fr) * 1990-10-23 1992-04-24 Rhone Poulenc Agrochimie Composes a groupe triazolopyridazine leurs preparations et compositions herbicides les contenant.
FR2676444B1 (fr) * 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
CN1038249C (zh) * 1991-08-28 1998-05-06 罗姆和哈斯公司 含有二氢哒嗪酮及其相关化合物的杀菌组合物
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
US20030176437A1 (en) * 2001-08-31 2003-09-18 D.M. Watterson Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
JP2008518955A (ja) * 2004-11-02 2008-06-05 ノースウェスタン ユニバーシティ ピリダジン化合物および方法
EP2592075B1 (en) * 2004-11-02 2015-04-29 Northwestern University Pyridazine compounds for the treatment of inflammatory diseases
US20100168120A1 (en) * 2006-04-28 2010-07-01 Neuromedix Inc. Salts of pyridazine compounds
EP2063894B1 (en) * 2006-04-28 2019-08-28 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
WO2007127474A2 (en) * 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
EP2142498A2 (en) * 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
EP2278879B1 (en) 2008-04-21 2016-06-15 PATH Drug Solutions Compounds, compositions and methods comprising oxadiazole derivatives
EP2341776A4 (en) * 2008-09-19 2012-05-30 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US20100267706A1 (en) * 2009-04-20 2010-10-21 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2510998B1 (fr) * 1981-08-07 1986-01-10 Sanofi Sa Nouveaux derives amines de la pyridazine, leur procede de preparation et les medicaments, a action desinhibitrice, qui en comportent
FR2510997A1 (fr) * 1981-08-10 1983-02-11 Sanofi Sa Nouveaux derives de la methyl-4 phenyl-6 pyridazine, procede pour leur preparation et medicaments actifs sur le systeme nerveux central en contenant
FR2540113A1 (fr) * 1983-01-27 1984-08-03 Sanofi Sa Acides derives de la pyridazine actifs sur le systeme nerveux central
US4565814A (en) * 1983-01-28 1986-01-21 Sanofi Pyridazine derivatives having a psychotropic action and compositions

Also Published As

Publication number Publication date
FI78691C (fi) 1989-09-11
EP0117779A1 (fr) 1984-09-05
FR2540113A1 (fr) 1984-08-03
AU2372984A (en) 1984-08-02
PT77993A (fr) 1984-02-01
CA1238637A (en) 1988-06-28
PH21162A (en) 1987-08-05
NZ206945A (en) 1987-07-31
KR840007586A (ko) 1984-12-08
KR910000638B1 (ko) 1991-01-31
FI78691B (fi) 1989-05-31
DE3480653D1 (de) 1990-01-11
ES8500243A1 (es) 1984-10-01
AR240045A1 (es) 1990-01-31
IE840149L (en) 1984-07-27
PL142340B1 (en) 1987-10-31
SG93690G (en) 1991-01-18
AU2142188A (en) 1989-03-16
ATE48417T1 (de) 1989-12-15
DK38984A (da) 1984-07-28
EP0117779B1 (fr) 1989-12-06
IL70756A (en) 1987-03-31
PT77993B (fr) 1986-04-10
DK38984D0 (da) 1984-01-27
OA07644A (fr) 1985-05-23
FI840323A (fi) 1984-07-28
US4721711A (en) 1988-01-26
YU14284A (en) 1986-12-31
ZA84502B (en) 1984-09-26
ES529081A0 (es) 1984-10-01
NO840313L (no) 1984-07-30
DK162985C (da) 1992-06-01
PL245931A1 (en) 1985-07-16
FR2540113B1 (fi) 1985-05-17
IE57054B1 (en) 1992-04-08
JPS59141564A (ja) 1984-08-14
IL70756A0 (en) 1984-04-30
MA20018A1 (fr) 1984-10-01
DK162985B (da) 1992-01-06
AU652118B2 (en) 1994-08-18
FI840323A0 (fi) 1984-01-26
HU193890B (en) 1987-12-28

Similar Documents

Publication Publication Date Title
DD220026A5 (de) Verfahren zur herstellung von in 3-stellung amino-substituierten pyridazin-derivaten
DE2100242C2 (de) 1-Methyl-2-(3a,4,5,6,7,7a-hexahydro-1,2-benzisoxazol-3-yl)-5-nitroimidazol, Verfahren zu dessen Herstellung und dieses enthaltende Veterinärarzneimittel
EP0136658B1 (de) 1-Benzyl-aminoalkyl-pyrrolidinone und ihre Säureadditionssalze, Verfahren zu ihrer Herstellung und Arzneimittel
DE9290063U1 (de) Chinuclidin-Derivate
DD285605A5 (de) Verfahren zur herstellung von chinuclidinderivaten
DE3441975C2 (fi)
DE2607592A1 (de) Acetylenderivate von aminosaeuren sowie verfahren zu deren herstellung
DE2065636A1 (de) Neue tricyclische verbindungen
DE2305092C2 (fi)
AT376977B (de) Verfahren zur herstellung von neuen 5-substituierten oxazolidin-2,4-dionen und ihren salzen
DD149071A5 (de) Herstellung 2-substituierter trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido eckige klammer auf 4,3-b eckige klammer zu indole
DE1802394A1 (de) Aminoguanidine,Verfahren zu ihrer Herstellung und ihre Verwendung
DE2458638C2 (de) 4'-substituierte 2-Methyl-3-piperidinopropiophenonderivate, Verfahren zu deren Herstellung und pharmakologische Zubereitungen, welche diese enthalten
DE2044172C3 (de) Pyrrolderivate, ein Verfahren zu ihrer Herstellung und Arzneimittel
DE3872213T2 (de) 5-substituierte ornithin-derivate.
DE2348973C3 (de) 1 -(m-Trifluormethylphenyl)-4-propyIpiperazin-derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2651789C2 (de) Purinderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
DE10048715A1 (de) Verwendung von Aminosäure zur Behandlung von Schmerz
DE1620295C3 (de) Isochinolo eckige Klammer auf 2,1-d eckige Klammer zu benzo eckige Klammer auf 1,4 eckige Klammer zu diazepin-6-one
DE1206437B (de) Verfahren zur Herstellung von neuen 4-Aza-thioxanthenderivaten
DE2322561A1 (de) Trisubstituierte imidazole
DE2354931C2 (de) trans-2-Phenylbicyclooctan-Verbindungen, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
DE2359537C2 (de) 6-Chlor-5-cyclohexylindan-1-carbohydroxamsäure, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DD227962A5 (de) Verfahren zur herstellung von pyrrolidionen mit wirkung auf das nervensystem
DE2540334C2 (de) Benzylaminoalkansäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee